EDENTREE ASSET MANAGEMENT Ltd Increases Position in Bruker Corporation $BRKR

EDENTREE ASSET MANAGEMENT Ltd grew its position in shares of Bruker Corporation (NASDAQ:BRKR) by 45.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 379,650 shares of the medical research company’s stock after purchasing an additional 118,750 shares during the period. Bruker makes up about 3.0% of EDENTREE ASSET MANAGEMENT Ltd’s holdings, making the stock its 12th largest holding. EDENTREE ASSET MANAGEMENT Ltd owned about 0.25% of Bruker worth $12,335,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of BRKR. Nisa Investment Advisors LLC lifted its stake in Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after acquiring an additional 487 shares in the last quarter. Huntington National Bank increased its stake in Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after purchasing an additional 645 shares during the period. Spire Wealth Management acquired a new stake in shares of Bruker during the second quarter worth about $32,000. True Wealth Design LLC boosted its stake in shares of Bruker by 16,716.7% in the second quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 1,003 shares during the period. Finally, Hantz Financial Services Inc. grew its holdings in shares of Bruker by 39.5% in the second quarter. Hantz Financial Services Inc. now owns 1,560 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 442 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total transaction of $98,400.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $6,319,395.60. The trade was a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BRKR shares. The Goldman Sachs Group reduced their target price on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a report on Friday, February 13th. Guggenheim increased their price objective on Bruker from $53.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, January 26th. UBS Group reissued a “neutral” rating and set a $49.00 target price on shares of Bruker in a research note on Friday, February 13th. Wells Fargo & Company increased their price target on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus target price of $50.38.

Bruker Stock Down 1.2%

Bruker stock opened at $38.28 on Friday. The stock has a market cap of $5.82 billion, a PE ratio of -255.20, a P/E/G ratio of 2.29 and a beta of 1.19. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The stock’s fifty day moving average is $46.15 and its two-hundred day moving average is $40.54. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $56.22.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. During the same quarter in the previous year, the company posted $0.76 EPS. The company’s revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.